Re­gen­eron re­veals da­ta be­hind de­pri­or­i­tized BC­MA/CD3 bis­pe­cif­ic: #AACR23

OR­LAN­DO – Re­gen­eron on Mon­day re­vealed the da­ta be­hind one of its BC­MA and CD3-di­rect­ed bis­pe­cif­ic an­ti­bod­ies that it has de­cid­ed not to take for­ward for mul­ti­ple myelo­ma.

The drug, REGN5459, may be ex­plored in oth­er in­di­ca­tions, said An­dres Sir­ul­nik, se­nior VP of trans­la­tion­al and clin­i­cal sci­ences in hema­tol­ogy at Re­gen­eron, and Karen Ro­driguez Lorenc, VP and BC­MA glob­al pro­gram head. But in mul­ti­ple myelo­ma, the com­pa­ny is in­stead fa­vor­ing lin­voseltam­ab, al­so known as REGN5458.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER